TopoTarget
 |
|
| Public (Nasdaq Copenhagen: TOPO) | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Copenhagen, Denmark |
|
Key people
|
Francois Martelet (co-foundar) Jean-Louis Misset (Global Medical and Scientific Advisory Board) |
| Revenue |
 DKK 43.979 million (2009), p. 24
|
 DKK 132.49 million (2009), p. 24
|
|
|
DKK 140.46 million (2009), p. 24
|
|
| Total assets |
DKK 585.41 million (2009), p. 24
|
| Total equity |
DKK 411.79 million (2009), p. 24
|
|
Number of employees
|
53 (2009), pp. 24; 68 (2008), p. 36;
|
| Website | http://www.topotarget.com/ |
Francois Martelet
(Chief Executive Officer)
Anders Fink Vadsholt
(CFO & Head of IR)
Bo Jesper Hansen
(Chairman of the Board)
TopoTarget (Nasdaq Copenhagen: TOPO) was a Copenhagen-based biotechnology company focused on the discovery and development of drugs and therapies to treat cancer. In 2014, it merged with BioAlliance Pharma and is now part of Onxeo.
It was founded in 2000 by a group of clinicians. TopoTarget was involved in collaborations with both academia and industry. In 2001 they began collaborating with the National Cancer Institute, a component of the US National Institutes of Health. Since their acquisition of Prolifix, they have been collaborating with the Netherlands Cancer Institute. They also collaborate with Rigshospitalet, the national hospital of Denmark. TopoTarget has also collaborated with other companies, including Novartis since 2003, and Lundbeck as of October 2007; Topotarget has been member of the Danish Innovation Network Biopeople since 2005.
In 2007, TopoTarget’s revenue was 44,890,000 DKK. The company is publicly traded on the OMX Nordic Exchange in Copenhagen under the symbol TOPO. They are a member of Medicon Valley Alliance. The CEO is Peter Buhl Jensen, M.D., Ph.D.
...
Wikipedia